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Abstract 
 CREBH (encorded by Creb3l3) is a liver and intestine-specific transcription 
factor. Recent papers reported that hepatic CREBH plays a key role in energy 
metabolism such as anti-obesity and anti-diabetes effects via increasing fatty acid 
lipolysis and gluconeogenesis during starvation. However, the function of intestinal 
CREBH remains to be determined. We generated transgenic mice that highly expressed 
the nuclear form of CREBH in the intestine, but weakly in the liver (CREBH-Tg mice). 
We fed CREBH-Tg mice with a lithogenic diet (LD). LD-fed CREBH-Tg mice showed 
decreased plasma cholesterol levels as well as prevention of fatty liver and cholesterol 
crystal formations in the gallbladder. CREBH-Tg mice increased fecal cholesterol 
output. In addition, we found that the expression of Npc1l1, a rate-limiting transporter 
mediating intestinal cholesterol absorption, was decreased in CREBH-Tg mice. 
Intestinal Srb1, Abca1, and Abcg5/8 expression were also reduced in CREBH-Tg mice. 
With luciferase assay, we showed that CREBH decreased mouse Npc1l1 promoter 
activity. These data suggest that the intestinal cholesterol absorption in CREBH-Tg 
mice is decreased. Collectively, these results support that intestinal CREBH prevents 
LD-induced hypercholesterolemia by decreasing expression of intestinal cholesterol 
transporters. 
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Chapter 1   
General Introduction 
 
1-1.  Cholesterol metabolism 
 In mammals, cholesterol is one of the essential structural components of the 
cell membrane, as well as a precursor molecule for steroid hormones and bile acids. 
Cholesterol is abundant in the blood stream and cell membrane [1]. Lathosterolosis, the 
diseases with cholesterol biosynthesis defect, show the importance of cholesterol in 
normal embryonic development. This disorder is characterized by low cholesterol levels 
in the tissues and blood, accompanied with multiple congenital anomalies, such as 
progressive cholestasis and microcephaly [2]. People who have high blood cholesterol 
levels have a greater risk of metabolic diseases such as cardiovascular diseases, NASH 
and gallstones. Increase cholesterol is estimated to cause 2.6 million deaths globally 
(4.5% of the total number of deaths) and 29.7 million disability adjusted life years [3]. 
A 10% reduction in plasma cholesterol in men aged 40 is considered to lead to a 50% 
reduction in heart disease within 5 years [4]. However, the picture of cholesterol 
metabolism is still incomplete. This study identified a novel mechanism to modulate 
cholesterol homeostasis.  
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 Cholesterol homeostasis is determined mainly by hepatic de novo synthesis, 
conversion into bile acids, and intestinal absorption. Dietary and biliary cholesterol is 
absorbed from the proximal part of small intestine [4]. About 80% of body cholesterol 
is derived form endogenous synthesis. HMGCR catalyzes the rate-limiting step [5]. 
About 23% of body cholesterol is in the brain, and is mainly synthesized in situ. Dietary 
cholesterol does not cross blood-brain barrier [2].  
 Lipoproteins are mainly synthesized in the liver and intestine. Lipoproteins 
play important roles in regulating the cholesterol transport to and from tissues through 
the bloodstream. After ingestion of a meal, dietary fat are absorbed into small intestine 
and form chylomicrons. Chylomicrons are particles that consists of triglycerides (85–
92%), phospholipids (6–12%), cholesterol (1–3%) and proteins (1–2%) [6]. 
Pre-chylomicron formation is followed by cellular lipid re-esterification and 
lipid-packaging with apoprotein B48. The pre-chylomicron is synthesized in the 
endoplasmic reticulum and transported to the Golgi. Fusion with the Golgi complex is 
required to form mature chylomicron particles. Mature chylomicrons contain ApoAI, 
ApoAIV, and ApoB48, and are secreted from the basolateral membrane of enterocytes. 
In the blood and lymph, lipoprotein lipase (LPL) mediates hydrolysis of triglycerides in 
chylomicrons. Free fatty acids are incorporated into muscle for energy production, 
brown adipose tissue for heat production and white adipose tissue for storage. 
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Chylomicron remnants are rapidly cleared by the liver. Intrahepatic lipids are 
repackaged and secreted as VLDL, which is hydrolyzed by LPL and converted to 
VLDL remnants (IDL), which is hydrolyzed by hepatic lipase, producing LDL. LDL 
transports cholesterol from the liver to the peripheral tissues [5] (Fig. 1-1).   
  
1-2.  Excessive cholesterol and related diseases 
 Excessive cholesterol level is one of the major risk factors leading to 
non-alcoholic fatty liver, cholesterol gallstone, and cardiovascular diseases. Cholesterol 
taken up by macrophages is oxidized. Oxycholesterol enhances cytokine production and 
yield of inflammatory cells. LDL-accumulated macrophages become foam cells on the 
arterial wall, which progress to atherogenic plaques, resulting in cardiovascular diseases 
such as coronary heart disease or stroke [5]. Cardiovascular diseases are a major cause 
of world-wide death. The current treatment guidelines describes that the patients who is 
at risk for these diseases should meet the defined targets for LDL-cholesterol levels. 
Consequently, a high number of individuals need to receive cholesterol-lowering 
therapy.  
 Concentrated bile, which is converted from cholesterol, is stored in the 
gallbladder. Gallstone disease is one of the most common biliary tract diseases in the 
world. The disease is sometimes accompanied with pain and inflammation of the 
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gallbladder, leading to receive considerable financial and social burdens [7]. The 
occurrence is due to the following five factors; genetic alteration of lithogenic genes, 
hepatic hypersecretion of bile and cholesterol, gallbladder hypomotility, accelerated 
phase transitions of cholesterol, and increased amount of cholesterol of intestinal origin 
due to high efficiency of cholesterol absorption [7]. Statin, a drug that inhibits hepatic 
cholesterol synthesis, reduces the cholesterol content in bile and prevents cholesterol 
crystals formation [8]. In addition, Ezetimibe, an intestinal cholesterol absorption 
inhibitor, has been shown to reduce bile cholesterol levels in gallstone patients by 
decreasing expression of NPC1L1, an intestinal cholesterol transporter [9]. 
 Lipid accumulation drives the development of progressive hepatic 
inflammation and fibrosis. Non-alcoholic fatty liver disease (NAFLD) is a chronic liver 
disease that is characterized by excessive lipid deposition in the liver. NAFLD is one of 
the most common liver disease and observed among 15-46% of adults in the USA[10], 
and the progressive state is defined as Non-alcoholic steatohepatitis (NASH). It is well 
known that dyslipidemia, obesity, diabetes and insulin resistance are the risk factors for 
the development of inflammation and steatosis in the liver [11]. 
 
1-3  Intestinal cholesterol absorption 
 Intestinal cholesterol absorption and excretion are important components of 
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cholesterol homeostasis. Bile salt micelles facilitate the transfer of cholesterol across the 
brush border membrane. Intestinal cholesterol absorption is a selective multistep 
process, which is regulated by multiple sterol transporter genes. NPC1L1 has been 
identified as a critical player for the uptake of cholesterol across the plasma membrane 
of intestinal enterocytes [12]. NPC1L1 undergoes clathrin-mediated internalization 
following sterol binding. The absorbed sterols are delivered to the endoplasmic 
reticulum (ER) for esterification. ACAT2 functions to convert cellular cholesterol into 
cholesterol ester [13]. Plant sterols are less effective substrates for ACAT2 and are 
secreted back into the intestinal lumen. SRB1 is a cholesterol transporter, which is 
involved in intestinal chylomicron production [14,15]. ATP binding cassette protein 
ABCA1 in the intestine forms HDL-cholesterol and transport from the epithelial cells 
into bloodstream [16]. Two hemi-ABC transporters, ABCG5 and ABCG8, dimerize to 
form a complete transporter to efflux cholesterol and plant sterols back into the lumen 
for fecal disposal [17,18]. These cholesterol transporters are highly expressed in the 
jejunum, where the nutrients are absorbed. Intestinal cholesterol ester forms 
chylomicron, and triglycerides are incorporated into chylomicron by microsomal 
triglyceride transfer protein (MTTP). The mature chylomicron enters the lymphatic 
circulation (Fig. 1-2). 
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1-4  The roles of CREBH in lipid and cholesterol metabolism 
 CREBH (encorded by Creb3l3) is a basic leucine zipper domain 
transcriptional factor of the CREB/activating transcription factor (ATF) family [19]. 
CREBH is highly and selectively expressed in gastrointestinal tract tissues including the 
liver, pyloric stomach, duodenum, and ileum [20]. CREBH is localized in the 
endoplasmic reticulum membrane. CREBH is activated and/or induced under various 
kinds of stresses including ER stress, pro-inflammatory cytokines, bacterial endotoxin 
LPS. CREBH is cleaved by Golgi-resident site-1 protease and site-2 protease, the same 
enzymes responsible for the cleavage of SREBPs, the regulators of lipid biosynthesis 
[21].  
 Our previous work showed that hepatic overexpression of nuclear CREBH led 
to therapeutic effects on diabetes and obesity. CREBH induced systemic lipolysis, 
hepatic ketogenesis and insulin sensitivity with increased energy expenditure. Hepatic 
CREBH induces anti-metabolic disorder hormones including FGF21 and IGFBP2 [22]. 
In addition, several papers have been reported a hepatic function of CREBH in 
triglyceride metabolism [23,24]. Hepatic CREBH induces the expression of LPL 
coactivaters such as ApoA4, ApoA5 and ApoC3, which reduces plasma triglyceride 
levels [23]. In an atherogenic diet-fed state, hepatic CREBH is involved in lipogenesis, 
FA oxidation, and lipolysis. However, the roles of intestinal CREBH remain to be 
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determined. In the present study, we revealed that intestinal CREBH decreased 
cholesterol transporter expression and prevents high cholesterol diet-induced 
hypercholesterolemia.  
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1-5.  Figures 
 
 
 
Figure 1-1.  Lipoprotein metabolism 
 Chylomicron remnants are rapidly cleared by the liver. Intrahepatic lipids are 
repackaged and secreted as VLDL, which is hydrolyzed by lipoprotein lipase (LPL) and 
converted to VLDL remnants (IDL), which is hydrolyzed by hepatic lipase (HL), 
producing LDL. LDL transports cholesterol from the liver to the peripheral tissues. 
HDL acquires cholesterol from peripheral tissues and transports the cholesterol back to 
the liver.  
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Figure 1-2.  The roles of intestinal cholesterol transporters 
 NPC1L1 is a rate limiting cholesterol transporter in the intestine. SRB1 is 
involved in chylomicron synthesis and cholesterol absorption. ABCA1 is involved in 
HDL-cholesterol synthesis. ABCG5/8 functions for reverse cholesterol transport from 
enterocytes to the lumen. LXR up-regulates the intestinal expression of ABCG5/8.  
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Chapter 2   
Analysis of metabolic phenotype of LD-fed CREBH-Tg mice 
 
2-1  Introduction 
 As mentioned above, the function of intestinal CREBH is poorly understood. 
Intestinal CREBH is highly expressed in the epithelial cells of jejunum. This part of 
intestine is important for nutrient absorption. Several cholesterol transporters, such as 
NPC1L1 and SRB1, are expressed in similar parts of intestine as CREBH. In this study, 
we investigated the effect of CREBH overexpression on cholesterol homeostasis and 
gene expression changes of intestinal cholesterol transporters. 
 
2-2  Materials and Methods 
Animals and diets 
 C57/BL6J (wild type [WT]) mice were obtained from CLEA Japan. To 
generate the active form of human CREBH transgenic mice, cDNA encoding the rat 
PCK1 promoter, human CREBH (1-320 amino acid residues), and the 3' 
polyadenylation signal of human growth hormone was microinjected into C57BL6J 
eggs. Mice were housed in a pathogen-free barrier facility with a 12 h light/dark cycle 
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and were given free access to water. Mice were fed with a normal chow diet (MF: 
Oriental Yeast, Tokyo, Japan) or a lithogenic diet (LD) (F2HFD1: Oriental Yeast, 
Tokyo, Japan) for 2 weeks. Age-matched males were used for each experiment. The 
mice were sacrificed during the light phase. Eight-week old mice were fed with an LD. 
After 2-week feeding, they were killed in a fed state. Plasma samples were collected 
from the post-orbital plexus. All animal husbandry and animal experiments were 
consistent with the University of Tsukuba’s Regulations of Animal Experiments and 
were approved by the Animal Experiment Committee of the University of Tsukuba. 
 
Plasma, hepatic, and gallbladder bile lipid and gallstone analysis 
 Plasma samples were collected from the post-orbital plexus using heparinized 
capillaries, and were examined for total cholesterol, triglyceride, bile acids, NEFA, 
glucose, ALT and AST. Hepatic lipids were extracted from liver tissues using Folch 
solution (chloroform-methanol, 2:1 v/v), dried and dissolved in 2-propanol. The hepatic 
lipid extracts were assayed for hepatic cholesterol and triglyceride levels. Gallbladder 
bile were collected from the gallbladder, diluted with water. The parameters were 
determined by the commercial assay kits (Cholesterol C-Test Wako, Triglyceride 
G-Test Wako, Total Bile Acids-Test Wako, Transaminase CII-Test Wako, Wako Pure 
Chemicals, Tokyo, Japan). The bile of the gallbladder was examined for monohydrate 
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cholesterol crystals under polarizing light microscopy.  
 
Fecal cholesterol and bile acids output 
 Mice were fed an LD for 2 weeks, and fresh feces were collected and dried. 
100 mg feces powders were mixed with 2 ml of Folch solution, which was also used for 
hepatic cholesterol measurement. The feces were incubated at 60ºC in a water bath over 
shaking for 1 hour; the tubes were centrifuged at 3000 rpm for 5 minutes, the 
supernatants were collected into a glass tube, dried up at 60Cº in the heat block, 
dissolved with 400 μl of isopropanol, and examined for cholesterol contents. For the 
measurement of fecal bile acids levels, 50 mg feces powders were mixed with 2.5 ml of 
99.5% EtOH in a glass tube with cap. The mixture was incubated at 65Cº in a water 
bath with shaking for 1 hour, and centrifuged at 3000 rpm for 5 minutes; the supernatant 
was transferred into a glass tube, and dried up completely in the heat block. The dried 
pellet was dissolved with 1 ml of 90% EtOH, and examined for bile acid contents The 
cholesterol and bile acid levels in the solutions were determined by Total Bile 
Acids-Test Wako (Wako Pure Chemicals, Tokyo, Japan).  
 
Analysis of gene expression 
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 RNA was extracted from frozen mouse tissues using Sepasol (Nakarai Tesque, 
Kyoto, Japan). For the analysis of jejunal gene expression, the fragment of the first 15% 
of the relative distance from pyloric sphincter to rectum was used. Total RNA was 
reverse transcribed using the PrimeScript RT Master kit (Takara, Bio Inc., Shiga, Japan). 
Real-time PCR was performed using ABI Prism 7300 System with LightCycler-DNA 
Master SYBR Green I Mix (Roche DIagnostics Ltd, Lewes, UK). mRNA expression 
was normalized to cyclophilin mRNA content and expressed as fold change compared 
to WT mice using the CT method. Microarray analysis was performed by TAKARA 
Bio Inc. using Agilent Expression Array. Heat maps were generated in R (v3.3.0) and 
bioconductor.  
 
Statistical analysis 
 All results are presented as means ±SEM. Data were analyzed using Student's 
t-test, and considered statistically significant if p < 0.05.   
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2-3  Results 
Generation of CREBH-Tg mice 
 To investigate the function of CREBH, we generated three lines of 
CREBH-Tg mice. In CREBH-Tg mice, the active form of human CREBH was 
overexpressed by the Pck1 promoter. One of the three lines of CREBH-Tg mice 
expressed the transgene highly in the liver. The line of CREBH-Tg mice used in this 
study expressed the transgene highly in the intestine, but scarcely in the liver (Fig. 2-1). 
In those mice, the hepatic expression of fgf21, the target gene of CREBH in the liver, 
tends to increase but did not change significantly. Thus, there was a low effect of the 
transgene in the liver of CREBH-Tg mice (Fig. 2-2). In this study, we used the line of 
CREBH-Tg mice to analyze the intestinal CREBH function rather than hepatic CREBH. 
The mice were fed an LD to check the effect of intestinal CREBH overexpression on 
cholesterol metabolism. There was no significant difference in BW, food intake, liver 
weight or WAT weight (Fig. 2-3). 
 
Intestinal CREBH protects against LD-induced hypercholesterolemia 
 Plasma lipid levels were measured to determine the effect of CREBH 
overexpression on LD-induced hypercholesterolemia. LD-feeding increased plasma 
cholesterol in WT mice and interestingly LD-fed CREBH-Tg mice showed lower 
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plasma cholesterol levels than WT mice (Fig. 2-4). It is known that NPC1L1 inhibitor 
improves LD-induced hypercholesterolemia not only in a fed state, but also in a fasted 
state [25] when the effect of biliary cholesterol re-absorption is well observed. Plasma 
triglyceride levels were not changed between chow-fed WT and CREBH-Tg mice (Fig. 
2-4). NEFA levels were lower in CREBH-Tg mice than WT mice on a chow diet (Fig. 
2-5). It has been reported that CREBH regulates lipolysis via inducing ApoA4 and 
ApoC2 expression in the liver and intestine [11], which might lower triglyceride and 
NEFA levels in CREBH-Tg mice. LD-feeding decreased plasma NEFA levels in both of 
WT and CREBH-Tg mice, therefore, LD-feeding might blunt the significant difference 
between WT and CREBH-Tg mice. Plasma bile acids levels were not changed 
significantly, neither in chow-fed or in LD-fed state (Fig. 2-5). Lipoprotein particle 
distributions were determined by HPLC analysis. This result showed that CREBH-Tg 
mice had higher plasma cholesterol levels at any lipoprotein fractions. Plasma ALT 
levels tended to be lower in CREBH-Tg mice than WT mice (Fig. 2-6). Collectively, 
these results showed that intestinal CREBH prevents LD-induced hypercholesterolemia.  
 We checked the liver histology and hepatic lipid contents in WT and 
CREBH-Tg mice fed an LD. CREBH-Tg mice had more reddish liver than WT mice 
when fed an LD (Fig. 2-7). This data indicated improved LD-induced fatty liver in 
CREBH-Tg mice. H&E staining of liver sections showed CREBH overexpression 
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decreased hepatic lipid accumulation (Fig. 2-7). Liver weight was not significantly 
changed between WT and CREBH-Tg mice. Liver cholesterol contents were lower in 
CREBH-Tg mice fed a LD (Fig. 2-8). Hepatic bile acids levels were not significantly 
changed (Fig. 2-8). These results show that intestinal CREBH prevents LD-induced 
cholesterol accumulation in the liver. 
 Several papers reported that NPC1L1 inhibition prevents gallbladder crystal 
formation under LD-feeding conditions [25,26]. We next checked gallbladder bile 
crystal formation in CREBH-Tg mice. Representative pictures of gallbladders of WT 
and CREBH-Tg mice fed with a LD. These pictures showed that gallbladder stones 
were accumulated in WT mice but scarcely in CREBH-Tg mice (Fig. 2-9). Gallbladder 
bile was checked by the light polarizing microscopy for the presence of cholesterol 
monohydrate crystals and sandy stones (Fig. 2-9). The average crystal stone size was 
decreased in CREBH-Tg mice compared to WT mice (Fig. 2-10). Cholesterol and bile 
acid levels in the gallbladder of CREBH-Tg mice were decreased (Fig. 2-10). 
Gallbladder phospholipid levels were not changed between groups (data not shown). 
These data suggested that intestinal CREBH plays an important role in gallbladder stone 
prevention.  
 Intestinal cholesterol contents were lower in LD-fed CREBH-Tg mice than in 
WT mice (Fig. 2-11). LD-fed CREBH-Tg mice increased fecal cholesterol output (Fig. 
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2-12). Fecal bile acids output was not significantly changed, compared to WT mice (Fig. 
2-12). It has been reported that inhibition of intestinal cholesterol absorption by 
ezetimibe treatment led to decreased intestinal cholesterol content and increased fecal 
cholesterol output in LD-fed mice [9,27]. Thus, these data suggested that the intestinal 
cholesterol absorption was reduced in LD-fed CREBH-Tg mice compared to WT mice. 
  
Intestinal cholesterol transporter expression was decreased in HCD-fed 
CREBH-Tg mice 
 We next investigated the mechanisms underlying the effect of intestinal 
CREBH on cholesterol homeostasis. Initially, we performed microarray analysis to 
compare the intestinal gene expression between WT and CREBH-Tg mice under chow- 
and LD-feeding, respectively. Interestingly, the data suggested that Npc1l1, Srb1 and 
Abca1 expression were decreased in the intestine of CREBH-Tg mice, on chow or LD 
diet. It has been well reported that NPC1L1 plays a critical role to transport cholesterol 
from the lumen to enterocyte [12,28]. Although there are conflicting reportsm, Srb1 and 
Abca1 have been also suggested to be involved in intestinal cholesterol absorption 
[29,30]. Next, we performed real time-PCR with intestinal mRNA of LD-fed WT and 
CREBH-Tg mice. We identified reductions of Npc1l1, Srb1, and Abca1 expression in 
the intestine of LD-fed CREBH-Tg mice, as well as of Abcg5, Abcg8 and Lxr (Fig. 
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2-13). It is known that NPC1L1 inhibition by ezetimibe treatment leads to decreased 
Abcg5/8 expression [8,26], which was consistent with the gene expression changes 
observed in the intestine of LD-fed CREBH-Tg mice. The reduction of intestinal Lxrβ is 
possibly due to reduced systemic cholesterol levels in LD-fed CREBH-Tg mice. 
Collectively, these results suggested that decreased Npc1l1 expression is one of the 
reason that CREBH-Tg mice showed anti-hypercholesterolemic phenotype when 
subjected to LD-feeding. To check the NPC1L1 protein levels in the intestine of 
chow-fed WT and CREBH-Tg mice, Western blotting was performed. We found that 
CREBH decreased Npc1l1 protein levels in the intestine (Fig. 2-14) 
 Cholesterol homeostasis is maintained as the balance of intestinal absorption, 
hepatic synthesis and hepatic conversion into bile acids. In order to check whether the 
metabolic phenotype of LD-fed CREBH-Tg mice was derived from the liver, we 
determined the expression of hepatic cholesterol synthesis and conversion genes. We 
performed real time-PCR with liver mRNA of LD-fed WT and CREBH-Tg mice (Fig. 
2-15). Hepatic lipid synthesis genes were not significantly changed in CREBH-Tg mice. 
FXR-SHP-Cyp7a1 pathway for bile acids synthesis was leaned toward decreased 
hepatic conversion of cholesterol in CREBH-Tg mice.  
 
2-4  Discussion 
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 We have demonstrated that the LD-induced hypercholesterolemia is 
prevented in CREBH-Tg mice. CREBH overexpression reduced intestinal cholesterol 
transporters expression, including Npc1l1, Abca1, Srb1 and Abcg5/8. LD-fed 
CREBH-Tg mice attenuated systemic hypercholesterolemia, accompanied with 
increased fecal cholesterol output.  
 NPC1L1 is a rate-limiting transporter of cholesterol absorption in small 
intestine and a key modulator of systemic cholesterol homeostasis [12]. Intestinal 
ABCA1 contributes to HDL biogenesis and plays an important role in intestinal 
cholesterol absorption [29,30]. Several papers suggest that SRB1 is involved in 
intestinal chylomicron production [31,32] and is responsible for the uptake of 
cholesterol from the lumen of the proximal small intestine into the brush border 
membrane [33,34], although the initial reports including the studies of global Srb1 
knockout mice have yielded conflicting result [35,36]. Intestinal Abcg5 and Abcg8, on 
the other hand, promote to excrete cholesterol from enterocytes into lumen [17,37]. We 
observed reduced expression of Npc1l1, Srb1, Abca1 and Abcg5/8 in the intestine of 
LD-fed CREBH-Tg mice. This gene expression change may lead to reduced intestinal 
cholesterol absorption, considering that intestinal cholesterol absorption was decreased 
in Npc1l1-Abcg5-Abcg8 triple knockout mice [38]. 
       Npc1l1, Srb1 and Abca1 expressions were decreased in both of chow-fed and 
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LD-fed CREBH-Tg mice. On the other hand, Abcg5/8 expression was reduced in 
LD-fed CREBH-Tg mice, but not in chow-fed mice. We though that the decreased 
Abcg5/8 expression in LD-fed CREBH-Tg mice was secondary to the decreased 
systemic cholesterol levels by decreased Npc1l1, Srb1, and Abca1 expression. LXR 
might not be activated in LD-fed CREBH-Tg mice as much as in WT mice, because 
systemic cholesterol levels were lower than in WT mice, which consequently led to 
lower expression of Abcg5/8, the LXR downstream genes.  
 
2-5  Conclusion 
 LD-fed CREBH-Tg mice showed reduced systemic cholesterol levels 
compared to WT mice. We found increased fecal cholesterol output in LD-fed 
CREBH-Tg, accompanied with decreased Npc1l1 expression in the intestine. Thus, 
these results suggest that LD-fed CREBH-Tg mice decreased intestinal cholesterol 
absorption possibly by reducing Npc1l1 expression. 
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2-6.  Figures 
 
       
 
 
Figure 2-1.  Tissue distribution of CrebH and CREBH expression 
Northern blotting was performed to examine the expression of CrebH and CREBH, 
using mRNAs extracted from CREBH-Tg mice.  
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Figure 2-2.  Hepatic expression of Fgf21 is not significantly changed in 
CREBH-Tg mice  
Hepatic Fgf21 expression of chow-fed WT and CREBH-Tg mice was determined by 
real time-PCR (n = 3/group). Results are presented as means ±SEM. 
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Figure 2-3.  Body and tissue weights of CREBH-Tg mice. 
Body weight, food intake, liver weight, WAT weight and food intake were measured in 
WT and CREBH-Tg mice fed on chow or LD fed states. Results are presented as means 
±SEM. 
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Figure 2-4.  Plasma cholesterol and triglyceride levels in CREBH-Tg mice. 
Plasma cholesterol and triglyceride levels were measured in WT and CREBH-Tg mice 
fed with a normal chow diet and an LD for 2 weeks (plasma cholesterol, n = 19-31, 
plasma triglyceride, n = 10-26/group). Results are presented as means ±SEM. 
Differences between genotypes on either nutrient state, **p < 0.01. Lipoprotein particle 
distributions were determined by HPLC analysis. 
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Figure 2-5.  Plasma NEFA and bile acid levels in CREBH-Tg mice. 
Plasma NEFA and bile acid levels were measured in WT and CREBH-Tg mice fed with 
a normal chow diet or an LD for 2 weeks (plasma bile acid n = 9-46/group, NEFA, n = 
14-23/group). Results are presented as means ±SEM. Differences between genotypes on 
either nutrient state, *p < 0.05.  
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Figure 2-6.  Plasma ALT and AST levels in CREBH-Tg mice. 
Plasma AST and ALT levels were measured in WT and CREBH-Tg mice fed with a 
normal chow diet or an LD for 2 weeks (n = 15-27/group). Results are presented as 
means ±SEM. Differences between genotypes on either nutrient state.  
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Figure 2-7.  Lower lipid accumulation contents in CREBH-Tg mice on an LD.  
The representative pictures of the livers collected from WT and CREBH-Tg mice fed an 
LD.  Hematoxylin and Eosin (H&E) staining was performed with the liver sections of 
LD-fed WT and CREBH-Tg mice.  
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Figure 2-8.  Lower cholesterol contents in the liver of CREBH-Tg mice on a LD.  
Liver cholesterol, triglyceride and bile acid levels were measured in CREBH-Tg mice 
fed an LD (n = 8-15/group). Results are presented as means ±SEM. ***p < 0.001, **p < 
0.01.  
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Figure 2-9.  Gallbladder crystal formation is prevented in the gallbladder of 
CREBH-Tg mice on an LD.  
Gallbladders were collected from LD-fed WT and CREBH-Tg mice. Representative 
pictures of the gallbladders are shown. Images of the gallbladder bile were analyzed by 
the light polarizing microscopy for the presence of cholesterol monohydrate crystal and 
sandy stones. The birefringence, or double refraction, was obtained as the 
decomposition of a ray of light into two rays when it passes through certain anisotropic 
materials. The blue color and yellow color in the picture stand for the opposite direction 
of reflection.  
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Figure 2-10.  Lower cholesterol contents in the gallbladder of CREBH-Tg mice on 
an LD.  
Cholesterol, triglyceride and bile acid levels were measured in the gallbladder of 
CREBH-Tg mice fed with an LD (n = 8-15). Results are presented as means ±SEM. **p 
< 0.01, *p < 0.05.  
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Figure 2-11.  Lower cholesterol levels in the intestine of CREBH-Tg mice on an 
LD.  
Intestinal cholesterol (n = 6/group) and triglyceride (n = 6/group) levels were measured 
from WT and CREBH-Tg mice fed an LD. Results are presented as means ±SEM. *p < 
0.05. 
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Figure 2-12.  Increased fecal cholesterol output in CREBH-Tg mice on an LD.  
Fecal cholesterol (n = 6/group) and bile acid output (n = 7-9/group) were measured 
from WT and CREBH-Tg mice fed an LD. Results are presented as means ±SEM. **p 
< 0.01. 
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Figure 2-13.  Reduced intestinal cholesterol transporter expression in CREBH-Tg 
mice.  
Intestinal mRNA were extracted from WT and CREBH-Tg mice fed an LD. Real 
time-PCR was performed to determine the expression of intestinal cholesterol 
transporters (n = 6-14/group). Results are presented as means ±SEM. ***p < 0.001, **p 
< 0.01, *p < 0.05. 
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Figure 2-14.  Reduced intestinal NPC1L1 levels in CREBH-Tg mice.  
Intestinal protein was extracted from WT and CREBH-Tg mice. Western blotting was 
performed to determine Npc1l1 protein levels. Results are presented as means ±SEM. 
*p < 0.05. 
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Figure 2-15.  Hepatic genes involved in lipid synthesis and cholesterol conversion 
in CREBH-Tg mice.  
Real time-PCR was performed to check hepatic genes involved in lipid synthesis and 
cholesterol conversion (n = 6-7/group). Results are presented as means ±SEM. *p < 
0.05. 
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Chapter 3   
Mechanism of intestinal CREBH in cholesterol homeostasis 
 
3-1  Introduction 
 CREBH is a transcriptional factor, which binds to the promoter region of its 
target genes and regulates the expressions. It has been reported that hepatic CREBH 
binds to the promoter region of target genes such as PEPCK, G6PC [39] and ApoA4 
[40]. Since NPC1L1 is known to be a rate limiting-cholesterol transporter in the 
jejunum [12,28] and Npc1l1 expression was reduced in the CREBH-Tg mice, we 
investigated whether intestinal CREBH binds to the Npc1l1 promoter region and 
regulates the promoter activity. 
 
3-2  Material and methods 
Cell culture, transfection, and luciferase assay 
 Caco-2 cells were grown routinely in flasks at 37ºC in a 5% CO2-95% air 
environment. Caco-2 cells were seeded at a density of 4 x 105 cells into 24-well plates. 
Twenty four hours later, 0.3 kbp-mouse Npc1l1 promoter-luciferase constructs and 
expression vector for CREBH and/or SREBP-2 were transfected using lipofectamine 
40 
3000 (Invitrogen, Grand Island, NY, USA). Renilla expression construct was 
co-transfected as an internal control for transfection efficiency. 48 hours after 
transfection, firefly luciferase activity was measured with a luciferase assay system 
(PicaGene, Toyo-Inki, Tokyo, Japan), and renilla activity was examined with renilla 
reporter assay system (Promega, Madison, WI, USA). The promoter activity was 
described as a ratio of luciferase to renilla activity in each sample. 
 
Electrophoretic mobility shift assay  
 We generated the HA-tagged active form of CREBH from an expression 
vector using an in vitro reticulocyte transcriptionetranslation system (Promega). We 
used the following sequences in the electrophoretic mobility shift assays (EMSAs): 
5'-ggaagttgacctcagaaggaggagatggaatggca-3' for -106 to -69 of the Npc1l1 promoter; 
5'-ggcaccatctgatgtaagggaagagaaaataaattattaa-3' for -75 to -33 of the Npc1l1 promoter; 
5'-gagaaaataaattattaaccagtacgg-3' for -53 to -23 of the Npc1l1 promoter; and 
5'-gtacggcccagtcctattggccccatgacagacgagg-3' for -32 to +5 of the Npc1l1 promoter. 
5'-gtacggcccagtcctattggccccTAATATAacgagg-3' for -32 to +5 of mutant Npc1l1 
promoter.  We incubated the in vitro-translated protein lysates and anti-HA antibodies 
(12CA5, Santa Cruz) in a reaction mixture as previously described and resolved the 
DNA protein complexes on a 4% polyacrylamide gel. 
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3-3  Results 
CREBH suppressed the transcriptional activity of NPC1L1 
 To determine whether CREBH regulates the Npc1l1 promoter activity, 
luciferase assay was performed using Caco-2 cells. The 300 bp Npc1l1 promoter was 
inserted into a luciferase vector. We found that CREBH reduced mouse Npc1l1 
promoter activity in Caco-2 cells (Fig. 3-1). It has been reported that intestinal 
SREBP-2 increased Npc1l1 promoter activity [14]. In this study, we observed that 
CREBH reduced SREBP-2-induced the Npc1l1 promoter activity (Fig. 3-2). These data 
suggested that CREBH suppresses the Npc1l1 promoter activity, including in the 
condition, in which SREBP2 induces Npc1l1 expression, such as upon LD-feeding.  
 
CREBH binds to the mouse Npc1l1 promoter  
 To confirm the binding site of CREBH in the mouse Npc1l1 promoter, we 
performed an EMSA assay. In vitro translated CREBH proteins bound to the -32 and +5 
bp region of the Npc1l1 promoter, but not to other regions (Fig. 3-3). Competing with 
the mutant probe reduced the binding of CREBH to the Npc1l1 promoter (Fig. 3-4). In 
the mutant probe, -7 to -2 bp was mutated in the -32 to +5 sequence of the Npc1l1 
promoter. The -7 to -2 bp sequence of the Npc1l1 promoter is similar to the CREBH 
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responsive element of PEPCK [38]. 
 
3-4  Discussion 
 These data demonstrated that CREBH directly binds to the Npc1l1 promoter 
region and reduces Npc1l1 promoter activity. Several papers reported that intestinal 
NPC1L1 expression is affected by PPARα, PPARδ, and SREBP-2 [41-44]. With the 
luciferase assay using a 300 bp-mouse Npc1l1 promoter, we observed that SREBP-2 
increased Npc1l1 promoter activity and CREBH reduced SREBP-2-induced NPC1L1 
promoter activity. This finding suggested that intestinal SREBP-2 and CREBH are 
coordinately involved in the process that ensures balanced systemic cholesterol levels.  
 From the data of EMSA, we showed that CREBH binds to the -32 to +5 bp 
sequence of the Npc1l1 promoter. Moreover, a -7 to -2 bp sequence of mutant Npc1l1 
promoter probe reduced the binding of CREBH to Npc1l1 promoter. The sequence is 
similar to the CREBH responsive element of PEPCK [39]. Therefore, the -7 to -2 bp 
sequence was considered as the CREBH responsive element in the Npc1l1 promoter. 
 
3-5  Conclusion 
 These in vitro studies using Caco-2 cells indicate that CREBH directly binds 
to the mouse Npc1l1 promoter and reduced the transcriptional activity. Moreover, 
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EMSA data suggested that the -7 to -2 bp sequence of Npc1l1 promoter is the CREBH 
binding element. NPC1L1 is a rate-limiting intestinal cholesterol transporter. Therefore, 
CREBH may prevent LD-induced hypercholesterolemia by directly reducing Npc1l1 
expression.   
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3-6.  Figures 
 
 
 
 
Figure 3-1.  CREBH reduces Npc1l1 promoter activity.  
Caco-2 cells were transiently transfected with mouse Npc1l1 promoter vector along 
with empty vector or nuclear form of CREBH vector in a dose-dependent manner (n = 
3/group). Results are presented as means ±SEM. ***p < 0.001. 
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Figure 3-2.  CREBH reduces SREBP-2-induced Npc1l1 promoter activity.  
The effects of CREBH and SREBP-2 on a series of Npc1l1 promoter luc vectors were 
determined (n = 3/group). Results are presented as means ±SEM. ***p < 0.001, **p < 
0.01, *p < 0.05.  
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Figure 3-3.  CREBH binds to the Npc1l1 promoter.  
An EMSA assay indicated that CREBH directly bound to the region from -32 to +5 bp 
of Npc1l1 promoter. 
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Figure 3-4.  A mutant probe reduces the binding of CREBH to the Npc1l1 
promoter.  
A mutant probe of Npc1l1 promoter was used as the compepitor to examine whether 
CREBH binds to the Npc1l1 promoter. The mutant probe was an oligonucleotide 
corresponding to the -32 to +5 bp sequence of Npc1l1 promoter, in which -7 to -2 bp 
was mutated. 
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Chapter 4   
Analysis of metabolic phenotype of LD-fed CrebH null mice  
 
4-1.  Introduction 
 Since we showed that CrebH overexpression reduces intestinal Npc1l1 
expression and prevented LD-induced hypercholesterolemia, we next examined the 
effect of CrebH depletion on cholesterol homeostasis. Previous studies identified severe 
hypertriglycemia in CrebH null mice [22-24], however, the effects of CrebH depletion 
on systemic cholesterol levels were not fully elucidated. In this study, we used CrebH 
null mice and examine the metabolic phenotype when the mice were fed with a LD. 
 
4-2.  Material and methods 
Animals and diets 
Creb3l3tm1.1Sad/J (CrebH null) mice were purchased from The Jackson Laboratory. 
CrebH null were housed as CREBH-Tg mice. All animal husbandry and animal 
experiments were consistent with the University of Tsukuba’s Regulations of Animal 
Experiments and were approved by the Animal Experiment Committee of the 
University of Tsukuba. 
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Plasma, hepatic, and gallbladder bile lipid and gallstone analysis 
 The experimental procedure was described in chapter 2-2 .  
 
Fecal cholesterol and bile acids output 
 The experimental procedure was described in chapter 2-2 .  
 
Analysis of gene expression 
 The experimental procedure was described in chapter 2-2.  
 
Statistical analysis 
 All results are presented as means ±SEM. Data were analyzed using Student's 
t-test, and considered statistically significant if p < 0.05. 
 
4-3  Results 
LD-fed CrebH null mice showed severe hypercholesterolemia.  
 To determine the effect of CrebH depletion on cholesterol metabolism, 
CrebH null mice were fed with an LD. The plasma, liver, and intestinal cholesterol 
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levels were measured. On contrary to the phenotype of LD-fed CREBH Tg mice, CrebH 
null mice showed higher levels of plasma, liver, and intestinal cholesterol, compared to 
the WT mice (Fig. 4-1,2,3). The representative pictures of the liver and H&E staining of 
liver section from WT and KO mice are shown. Severe fatty liver was observed in 
LD-CrebH null mice (Fig. 4-4).  
 
LD-fed CrebH null mice showed increased fecal output and a tendency of increased 
intestinal Npc1l1 expression.  
 CrebH null mice had lower fecal cholesterol output (Fig. 4-5). Real time-PCR 
was performed to assess jejunal gene expression in LD-fed CrebH null mice. Jejunal 
Npc1l1 expression was increased in a chow-fed CrebH null mice, however, there was 
no clear difference between WT and CrebH null mice under LD-feeding (Fig. 4-6). It is 
known that increased systemic cholesterol levels suppress Npc1l1 expression. Thus, 
severe hypercholesterolemia might inhibit the Npc1l1 expression in LD-fed CrebH null 
mice. It is still expected that increased jejunal Npc1l1 expression in initial stage of LD 
feeding contributed to the metabolic changes of CrebH null mice fed with a LD for 2 
weeks. It should also be mentioned that hepatic CrebH null depletion would also lead to 
the hypercholesterolemic phenotype, as we previously reported that CrebH null affects 
hepatic Srebf2 and the expression of its target genes [45]. 
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4-4  Discussion 
 These results showed severe hypercholesterolemia in LD-fed CrebH null 
mice, compared to WT mice. This is the opposite outcome compared to LD-fed 
CREBH-Tg mice. In CrebH null mice, both hepatic and intestinal CrebH expression 
were depleted, thus, it can not be determined whether the metabolic phenotype was 
derived from hepatic and/or intestinal CrebH. We observed that intestinal Npc1l1 
expression was significantly increased in chow-fed CrebH null mice and tended to 
increase in LD-fed CrebH null mice. Thus, the increase of intestinal cholesterol 
transport may partially explain the severe hypercholesterolemia in CrebH null mice.    
 We previously reported that liver-specific CrebH null mice fed with a chow 
diet showed higher plasma cholesterol, triglyceride and NEFA levels compared to 
control mice. Hepatic cholesterol synthesis gene expression is altered in the liver of 
liver-specific CrebH null mice, which causes increased plasma cholesterol levels [22]. 
A recent paper also mentioned that hepatic CREBH decreased plasma cholesterol levels 
in Ldlr-/- mice [46]. Therefore, both intestinal and hepatic CREBH are involved in 
cholesterol metabolism. Interestingly, we observed decreased plasma cholesterol levels 
in chow-fed CREBH null mice, which is consistent with the data from an earlier paper 
[47]. These observations suggest that multiple hepatic genes may be related to the 
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alteration of cholesterol metabolism in CrebH null mice. Another paper reported that 
plasma cholesterol levels was not significantly changed in CrebH null mice fed with a 
diet containing 1.25% and 0.5% cholic acids for 6 months [22], although we observed 
increased plasma cholesterol levels in CrebH null mice fed with a LD for 2 weeks. A 
high cholesterol diet suppresses intestinal Npc1l1 expression, therefore, is difficult to 
observe the difference of plasma cholesterol levels between WT and CrebH null mice 
under a long term feeding of a high cholesterol diet. 
 
4-5  Conclusion 
 CREBH depletion led to severe hypercholesterolemia in mice fed with an LD. 
In addition, CREBH depletion increased cholesterol output and tendency of increased 
intestinal cholesterol Npc1l1 expression. Our observations suggest that intestinal 
CREBH plays an important role in cholesterol homeostasis.  
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4-6.  Figures 
 
 
 
 
Figure 4-1.  Hypercholesterolemia in LD-fed CrebH null mice.  
Plasma cholesterol (n = 6-11/group), triglyceride (n = 10/group) and NEFA (n = 
10/group) levels in LD-fed WT and CrebH null mice. Results are presented as means 
±SEM. **p < 0.01.  
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Figure 4-2.  Increased cholesterol and triglyceride content in LD-fed CrebH null 
mice.  
Liver cholesterol and triglyceride levels in LD-fed WT and CrebH null mice were 
measured (n = 6-10/group). Results are presented as means ±SEM. ***p < 0.001, **p < 
0.01.  
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Figure 4-3.  Increased intestinal cholesterol levels in LD-fed CrebH null mice.  
Fecal cholesterol output was examined in WT and CrebH null mice (n = 4-5/group). 
Results are presented as means ±SEM. **p < 0.01.  
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Figure 4-4.  Severe lipid accumulation was observed in the liver of LD-fed CrebH 
null mice.  
Representative pictures of liver from LD-fed WT and CrebH null mice are shown, as 
well as H&E stainings of liver sections from LD-fed WT and CrebH null mice.  
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Figure 4-5.  Reduced fecal cholesterol output in LD-fed CrebH null mice.  
Fecal cholesterol output was examined in WT and CrebH null mice (n = 4-5/group). 
Results are presented as means ±SEM. *p < 0.05.  
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Figure 4-6.  Intestinal expression of Npc1l1 in chow-fed and LD-fed WT and 
CrebH null mice  
Intestinal Npc1l1 expression of chow fed and LD-fed WT and CrebH null mice were 
determined by real time-PC. Results are presented as means ±SEM. **p < 0.01, *p < 
0.05.  
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Chapter 5 
Conclusions 
 
 CREBH is a transcription factor expressed selectively in the liver and 
intestine. Its metabolic effect has recently been investigated. Although the mechanism 
underlying anti-hypertriglyceridemic effects of hepatic CREBH was reported, the roles 
of intestinal CREBH remains to be determined. The present study demonstrated an 
anti-hypercholesterolemic effect of intestinal CREBH in the mice fed with a LD. 
CREBH overexpression reduced the expression of intestinal cholesterol transporters, 
including NPC1L1, ABCA1, SRB1 and ABCG5/8. LD-fed CREBH-Tg mice attenuated 
systemic hypercholesterolemia, accompanied with increased fecal cholesterol output. 
These findings suggests decreased intestinal cholesterol absorption in LD-fed 
CREBH-Tg mice. In addition, we found that CREBH decreased NPC1L1 promoter 
activity with in vitro experiments using Caco-2 cells. Collectively, These results suggest 
that intestinal CREBH reduces intestinal absorption of dietary cholesterol at least via 
regulating Npc1l1 expression. 
       There was no significant change of systemic cholesterol levels in chow-fed 
CREBH-Tg mice. Considering that Npc1l1 depletion did not reduce plasma cholesterol 
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levels in chow-fed mice [3], a plasma cholesterol-lowering effect by intestinal CREBH 
overexpression may be observed in a LD-fed state, but not in a chow-fed state. 
       As recent studies demonstrated that CREBH regulates ApoA4 and ApoC2 
expression [46-48], we found the increased expression of ApoA4 and ApoC2 in the 
intestine of CREBH-Tg mice while decreased expression of ApoA4 and ApoC2 in 
CrebH null mice. ApoA4 and ApoC2 are involved in intestinal chylomicrons secretion. 
However, we found that fecal triglyceride output was not significantly changed by 
CREBH overexpression. This is consistent with the result of a previous paper showing 
that CrebH depletion did not affect dietary fat absorption [39]. 
 This work suggests that intestinal CREBH functions as a metabolic regulator 
to prevent diet-induced hypercholesterolemia and cholelithiasis, at least via affecting 
expression of Npc1l1. This may indicate that the combination of therapeutic effects of 
hepatic and intestinal CREBH could be a future therapeutic target in the treatment of 
dyslipidemia and its related metabolic diseases. 
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5.  Figure 
 
 
 
Figure 5.  Intestinal CREBH reduces intestinal expression of NPC1L1 and 
prevents LD-induced systemic hypercholesterolemia and cholelithiasis   
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List of abbreviations 
ABCA1  ATP-binding cassette transporter A1 
ABCG5/8 ATP-binding cassette transporter G5/8 
ACAT2  Acyl cholesterol acyltransferase-2  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
CREBH  Cyclic AMP-responsive element-binding protein 3-like 3  
FGF21  Fibroblast growth factor 21 
HL  Hepatic lipase 
HMGCR 3-hydroxy-3-methylglutaryl coenzyme A reductase  
HPLC  High performance liquid chromatography 
IGFBP2  Insulin growth factor binding protein 2  
LD  Lithogenic diet 
LDL  Low-density lipoprotein  
LDLR  Low-density lipoprotein receptor 
LPL  Lipoprotein lipase  
LPS  Lipopolysaccharide 
NAFLD  Non-alcoholic fatty liver disease 
NASH  Non-alcoholic steatohepatitis  
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NEFA  Non-esterified fatty acids 
NPC1L1  Niemann-Pick C1-like 1  
PPAR  Peroxisome proliferator-activated receptor 
SREBP  Sterol response element-binding proteins 
SRB1  Scavenger receptor B1 
VLDL  Very low-density lipoproteins 
WAT  White adipose tissue 
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